Mineralocorticoid Receptor Antagonist Treatment for Steroid-Induced Central Serous Chorioretinopathy Patients with Continuous Systemic Steroid Treatment
المؤلفون المشاركون
Kim, Dong Yoon
Chae, Ju Byung
Kim, Jin Young
Kim, Jisoo
المصدر
العدد
المجلد 2018، العدد 2018 (31 ديسمبر/كانون الأول 2018)، ص ص. 1-7، 7ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2018-07-22
دولة النشر
مصر
عدد الصفحات
7
التخصصات الرئيسية
الملخص EN
Purpose.
To investigate the effectiveness of mineralocorticoid receptor (MR) antagonist in patients with steroid-induced central serous chorioretinopathy (CSC).
Methods.
A retrospective review was conducted of steroid-induced CSC patients who were treated with the MR antagonist spironolactone 50 mg once per day for at least 1 month.
The primary outcome measure was complete resolution rate of subretinal fluid (SRF) after spironolactone treatment.
Secondary outcomes included central subfield thickness (CST), subfoveal choroidal thickness (SFCT), and best-corrected visual acuity (BCVA) changes after spironolactone treatment.
Results.
Seventeen eyes from 15 patients were included in this study.
Conditions warranting chronic systemic steroid use were myasthenia gravis (6/15, 40%), glomerulonephritis (5/15, 33.3%), and organ transplantation (4/15, 26.7%).
Mean symptom duration of CSC was 4.00 ± 3.04 months.
After spironolactone treatment, 14 eyes (82.4%) showed complete resolution of SRF (P<0.001) without discontinuation of systemic steroid.
CST and BCVA were significantly improved after spironolactone treatment.
SFCT was significantly decreased after spironolactone treatment.
No patients experienced electrolyte imbalance after spironolactone treatment.
Conclusion.
MR antagonist treatment may be a therapeutic option for steroid-induced CSC patients.
This treatment modality may be especially beneficial for steroid-induced CSC patients who cannot discontinue steroid medication due to systemic conditions.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Kim, Jin Young& Chae, Ju Byung& Kim, Jisoo& Kim, Dong Yoon. 2018. Mineralocorticoid Receptor Antagonist Treatment for Steroid-Induced Central Serous Chorioretinopathy Patients with Continuous Systemic Steroid Treatment. Journal of Ophthalmology،Vol. 2018, no. 2018, pp.1-7.
https://search.emarefa.net/detail/BIM-1196546
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Kim, Jin Young…[et al.]. Mineralocorticoid Receptor Antagonist Treatment for Steroid-Induced Central Serous Chorioretinopathy Patients with Continuous Systemic Steroid Treatment. Journal of Ophthalmology No. 2018 (2018), pp.1-7.
https://search.emarefa.net/detail/BIM-1196546
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Kim, Jin Young& Chae, Ju Byung& Kim, Jisoo& Kim, Dong Yoon. Mineralocorticoid Receptor Antagonist Treatment for Steroid-Induced Central Serous Chorioretinopathy Patients with Continuous Systemic Steroid Treatment. Journal of Ophthalmology. 2018. Vol. 2018, no. 2018, pp.1-7.
https://search.emarefa.net/detail/BIM-1196546
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1196546
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر